Public record
Semax: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Product listings
FDA product listings naming semax
The FDA NDC Directory holds 8 listings naming semax from 8 firms: 8 bulk ingredient listings and 0 finished product listings, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming semax | 8 | |
| Bulk ingredient listings | 8 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 4 | |
| Finished product listings | 0 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 8 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains semax
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
Published research
Published papers mentioning semax
PubMed indexes 210 papers that mention semax in the title or abstract, 56 of them published from 2016 to 2025. The count for 2025 is 8 and for 2024 is 4.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 210 | |
| Published 2016 to 2025 | 56 | |
| Published in 2025 | 8 | |
| Published in 2024 | 4 | |
| Busiest year since 2016 | 2021 | 9 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'semax' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.